Related Experiment Video

Updated: Feb 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

J Cassinello1, J Á Arranz2, J M Piulats3

  • 1Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain. jcassinelloespinosa@gmail.com.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|November 15, 2017
PubMed

Insights

Androgen deprivation therapy was the primary treatment for metastatic prostate cancer. Newer drugs and earlier use of chemotherapy have improved survival for castration-resistant prostate cancer (CRPC) and hormone-sensitive disease.

Area of Science:

  • Oncology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) was the historical standard for metastatic prostate cancer.
  • Docetaxel offered the sole survival benefit in castration-resistant prostate cancer (CRPC).

Purpose of the Study:

  • To outline the current treatment landscape for prostate carcinoma.
  • To review recent advancements in prostate cancer therapy.

Main Methods:

  • Literature review of recent clinical trials and treatment guidelines.
  • Analysis of drug approvals and treatment setting shifts.

Main Results:

  • Multiple agents (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223) are now approved for CRPC.
  • Docetaxel and abiraterone are now utilized in the hormone-sensitive setting, improving survival.

Conclusions:

  • The treatment paradigm for prostate cancer has evolved significantly.
  • Recent therapeutic advancements offer improved outcomes for patients with both hormone-sensitive and castration-resistant disease.
Keywords:
AbirateroneAndrogen deprivation treatmentCabazitaxelCastration-resistant prostate cancerDocetaxelEnzalutamideHormone-sensitive advanced prostate cancerRadium 223

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

901
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K